Exscientia, University of Oxford to develop treatments for Alzheimer’s disease
The collaboration will focus on a specific neuroinflammatory pathway associated with the development of AD
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Feb 21
The collaboration will focus on a specific neuroinflammatory pathway associated with the development of AD
11 Dec 20
The acquisition will help expand Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumours
10 Dec 20
Exscientia intends to use its AI-based Centaur platforms for genome scale AI-drug discovery and address critical global health…
08 Dec 20
Pfizer will leverage its extensive data and expertise, while PostEra its technology capabilities to advance the preclinical drug…
27 Nov 20
CX-5461 works to stabilise DNA G-quadruplexes of cancer cells and facilitates disruption of the replication fork in cancer…
27 Oct 20
Bayer will add AskBio’s advanced adeno-associated virus (AAV)-based gene therapy platform to its cell and gene therapy (CGT)…
03 Sep 20
Janssen’s decision is based on results from the interim analyses of the Phase 3 clinical study of Pimodivir…
26 Aug 20
As part of the agreement, Takeda and Engitix will complete validation and preclinical development of new therapeutics for…
20 Aug 20
CARE is a new public-private partnership that brings together scientists from academia, research centres, SMEs, EFPIA member companies…
14 Jul 20
Dr Tim Guilliams, CEO of UK biotech firm Healx, discusses three key ways AI has helped healthcare providers…